Growth Metrics

Aura Biosciences (AURA) Free Cash Flow (2020 - 2026)

Aura Biosciences filings provide 7 years of Free Cash Flow readings, the most recent being -$29.9 million for Q1 2026.

  • Quarterly Free Cash Flow fell 27.06% to -$29.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$91.6 million through Mar 2026, down 16.18% year-over-year, with the annual reading at -$85.2 million for FY2025, 6.7% down from the prior year.
  • Free Cash Flow hit -$29.9 million in Q1 2026 for Aura Biosciences, down from -$20.6 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$10.5 million in Q2 2022 and bottomed at -$29.9 million in Q1 2026.
  • Average Free Cash Flow over 5 years is -$18.5 million, with a median of -$17.5 million recorded in 2022.
  • The largest annual shift saw Free Cash Flow crashed 203.36% in 2022 before it grew 10.37% in 2025.
  • Aura Biosciences' Free Cash Flow stood at -$17.5 million in 2022, then decreased by 3.29% to -$18.0 million in 2023, then dropped by 27.74% to -$23.0 million in 2024, then rose by 10.37% to -$20.6 million in 2025, then crashed by 44.89% to -$29.9 million in 2026.
  • Per Business Quant, the three most recent readings for AURA's Free Cash Flow are -$29.9 million (Q1 2026), -$20.6 million (Q4 2025), and -$20.2 million (Q3 2025).